Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.
Investor's Business Daily on MSN
Nuvalent Unveils A New Promise For Hard-To-Treat Lung Cancer
Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental ...
Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...
October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
Lung cancer is a disease in which abnormal cells grow uncontrollably in the tissues of the lungs, forming tumors that can ...
Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in ...
Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...
The 5-year lung cancer survival rate has increased more than 25% over the past decade, highlighting the impact of increased ...
Traditionally, lung cancer is associated with older patients, specifically men who smoked. But doctors say that's beginning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback